Curaleaf Holdings Earnings Call Highlights Mixed Progress

Curaleaf Holdings (OTC) ((TSE:CURA)) has held its Q4 earnings call. Read on for the main highlights of the call.

Curaleaf Holdings’ latest earnings call painted a cautiously optimistic picture, with solid operational execution and improving productivity set against persistent pricing pressure and ongoing losses. Management highlighted stronger yields, brand traction and a successful refinancing as de‑risking moves, yet admitted that elevated costs and industry headwinds will weigh on profitability in the near term.

Revenue Rebound Marks Best Quarter in Six

Curaleaf reported fourth quarter revenue of $333 million, up 5% sequentially and 2% year over year, marking its strongest top‑line performance in six quarters. The rebound signals improving demand and operational stability, even as management stressed that growth is coming in a challenging pricing environment.

Full-Year Performance Shows Scale but Thin Margins

For the full year, Curaleaf generated $1.27 billion in revenue with an adjusted gross margin of 50% and adjusted EBITDA of $275 million, or 22% of sales. These figures confirm that the company has significant scale, but also underscore that profitability remains modest relative to revenue, especially given ongoing margin pressure and net losses.

International Business Becomes a Growth Engine

International operations are emerging as a key growth driver, with Curaleaf International delivering Q4 revenue of $51 million, up 10% sequentially and 65% year over year. Full‑year international sales reached $172 million, up roughly 63% versus the prior year and now tracking at an annual run rate above $200 million.

Productivity Gains Fuel Margin Expansion

Adjusted gross margin expanded to 49% in Q4, up 20 basis points year over year, and reached 50% for the full year, an improvement of 150 basis points. Management attributed the gains to doubled cultivation yields, better productivity and record average flower potency of 31%, highlighting operational levers that are partially offsetting price pressure.

Cash Generation Supports Balance Sheet Flexibility

Curaleaf generated $42 million of operating cash flow from continuing operations and $25 million of free cash flow in Q4, underpinning its ability to invest while servicing debt. For the year, operating cash flow reached $152 million and free cash flow $89 million, with a year‑end cash balance of $102 million providing a liquidity cushion.

Brands and Innovation Gain Market Share

On the brand front, Anthem pre‑rolls quickly became a top‑five national pre‑roll brand across four launch markets, showing rapid consumer adoption. Select maintained the number one vape share while Curaleaf captured the leading overall market share per Hoodie Analytics, with management planning additional innovation via the Briq 2.0 vape platform and Dark Heart premium products.

Wholesale Strength and Dispensary Footprint Expansion

Wholesale revenue climbed 15% year over year to $91 million, representing 27% of total sales and signaling healthier demand from third‑party retailers. The company also expanded its retail footprint by opening nine new dispensaries during the year, including five in Florida, three in Ohio and one in Maine.

Refinancing Extends Maturities but at a Price

Curaleaf completed a major refinancing, replacing prior senior secured notes with a new $500 million senior secured note carrying an 11.5% coupon and maturing in 2029. The transaction extended debt maturities and reduced near‑term refinancing risk while demonstrating investor appetite, and the company also reduced acquisition‑related debt by $57 million over the year.

Price Compression Remains a Structural Headwind

Despite operational improvements, Curaleaf faced a third straight year of double‑digit price compression across most U.S. markets, a trend that continued to weigh on revenue quality and margins. Management does not expect relief before at least the first half of 2026, underscoring that industry oversupply and competition are still pressuring realized pricing.

Persistent Net Losses Underscore Profitability Challenge

The company posted a Q4 net loss from continuing operations of $49 million, or $0.06 per share, with an adjusted net loss of $39 million, or $0.05 per share. For the full year, Curaleaf reported a net loss of $202 million and an adjusted net loss of $176 million, highlighting that, despite scale and cash generation, the business remains unprofitable on a net basis.

Adjusted EBITDA Margin Slips as Costs Bite

Adjusted EBITDA for Q4 came in at $69 million, down 9% versus the prior year, with adjusted EBITDA margin dropping to 21%, a 260‑basis‑point decline. For the full year, the adjusted EBITDA margin was 22%, down 100 basis points year over year, with management noting that the international segment alone reduced Q4 EBITDA by about 120 basis points.

SG&A Growth Limits Operating Leverage

Selling, general and administrative costs continued to rise, reaching $111 million in Q4, with core SG&A of $107 million up roughly $10–11 million from a year earlier. Core SG&A represented 32% of Q4 revenue, up 260 basis points, and 33% of full‑year sales, signaling that Curaleaf has yet to fully translate its revenue base into stronger operating leverage.

High-Cost Leverage Remains a Key Risk

Total outstanding debt stood at $549 million at quarter‑end, including the new $500 million note at an 11.5% interest rate. While the refinancing pushed maturities out to 2029 and eased near‑term pressure, the high coupon underscores that Curaleaf’s debt load remains costly and is likely to continue weighing on earnings.

Inventory Build and Capex Fund Growth Initiatives

Inventory rose by $8 million, or 4% year over year, largely driven by international expansion and anticipation of future demand. Capital expenditures totaled $63 million for the year, and management plans to lift capex to about $80 million in 2026 to support international projects, automation, store relocations and a headquarters move.

Strategic Exits Reflect Regulatory and Market Shifts

Curaleaf has deliberately exited its hemp operations and Missouri market, describing hemp revenue as de minimis but acknowledging a shrinking near‑term opportunity set. These exits signal a sharpening focus on regulated cannabis channels and a willingness to pivot in response to evolving regulatory landscapes and profitability considerations.

Near-Term Revenue Dip Expected on Seasonality

Management guided that first quarter revenue will be down mid‑single digits sequentially from Q4’s $333 million, citing normal seasonal patterns. The outlook suggests a temporary step back in growth as consumers and wholesale customers recalibrate following a strong year‑end period.

Guidance Points to Investment and International Upside

Looking ahead, Curaleaf expects Q1 revenue to dip sequentially but plans roughly $80 million of 2026 capex to fuel international expansion, automation and store upgrades, including at least 10 new dispensaries. International gross margins are projected to stay in the low‑to‑mid 40% range in 2026, improving toward about 50% as scale builds by 2027, while management believes a scheduled federal hemp ban could stabilize pricing later in the year and push more demand back into regulated channels.

Curaleaf’s earnings call underscored a company executing well on operations and brand building while still wrestling with structural industry pressures and a heavy, expensive balance sheet. For investors, the story is one of tangible progress in productivity, international growth and liquidity, offset by ongoing losses and narrowing margins that keep the risk‑reward profile finely balanced.